Response to crizotinib rechallenge after initial progression and intervening chemotherapy in ALK lung cancer

Journal of Thoracic Oncology

Volumn 8, Issue 3, 2013, Pages

  Browning, Eiko Theodora ^a   Weickhardt, Andrew James ^a   Camidge, D Ross ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CARBOPLATIN; CRIZOTINIB; PACLITAXEL; PEMETREXED;

ADULT; ARTICLE; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; LUNG ADENOCARCINOMA; LUNG RESECTION; MEDIASTINUM METASTASIS; PRIORITY JOURNAL; RETROPERITONEAL CANCER; STEREOTACTIC BODY RADIATION THERAPY; STEREOTACTIC RADIOSURGERY; TREATMENT OUTCOME;

ADENOCARCINOMA; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84874045943     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31827a892c     Document Type: Article

References (5)

1. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363: 1693-1703.
2. Weickhardt AJ, Scheier B, Burke JM, et al. Continuation of EGFR/ALK inhibition after local therapy of oligoprogressive disease in EGFR mutant (Mt) and ALK+ non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 2012;30: 7526.
3. Camidge DR, Kono SA, Lu X, et al. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J Thorac Oncol 2011;6: 774-780.
4. Shaw AT, Kim DW, Nakagawa K et al. Phase III study of Crizotinib vs. Pemetrexed or Docetaxel Chemotherapy in patients with advanced ALK-Positive NSCLC (PROFILE 1007). ESMO 2012 Meeting Abstracts Abstract 2862.
5. Becker A, Crombag L, Heideman DA, et al. Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment. Eur J Cancer 2011;47: 2603-2606.